Literature DB >> 15522037

Antimicrobial drug development--the past, the present, and the future.

J H Powers1.   

Abstract

Antimicrobial resistance has been an issue since the introduction into clinical use of the first agents in the 1940s. Although the discovery and development of new classes of antimicrobials through the 1960s presented an array of treatment options, these options for some serious and life-threatening infectious diseases may now be more limited. This paper examines the history of antimicrobial development, showing how the challenges in discovering new classes of drugs have been with us for the last 40 years. The present state of antimicrobial discovery and development is shaped by these challenges as well as by the economic realities of the pharmaceutical industry. This paper also discusses some of the regulatory considerations in antimicrobial drug development, and presents some potential solutions to the challenges inherent in antimicrobial drug development, including steps taken by the US Food and Drug Administration to streamline the drug review process for antimicrobial agents while maintaining the standards necessary to protect and promote the health of the public.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522037     DOI: 10.1111/j.1465-0691.2004.1007.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  31 in total

Review 1.  Novel classes of antibiotics or more of the same?

Authors:  Anthony R M Coates; Gerry Halls; Yanmin Hu
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 2.  Past and Present Perspectives on β-Lactamases.

Authors:  Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  The combination of osthole with baicalin protects mice from Staphylococcus aureus pneumonia.

Authors:  Shui Liu; Bowen Liu; Zhao-Qing Luo; Jiaming Qiu; Xuan Zhou; Gen Li; Bing Zhang; Xuming Deng; Zhenguo Yang; Jianfeng Wang
Journal:  World J Microbiol Biotechnol       Date:  2016-11-23       Impact factor: 3.312

4.  Signal Biosynthesis Inhibition with Ambuic Acid as a Strategy To Target Antibiotic-Resistant Infections.

Authors:  Daniel A Todd; Corey P Parlet; Heidi A Crosby; Cheryl L Malone; Kristopher P Heilmann; Alexander R Horswill; Nadja B Cech
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Miltefosine Reduces the Cytolytic Activity and Virulence of Acinetobacter baumannii.

Authors:  Steven E Fiester; Brock A Arivett; Amber C Beckett; Benjamin R Wagner; Emily J Ohneck; Robert E Schmidt; Jennifer T Grier; Luis A Actis
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  Improved adsorption of an Enterococcus faecalis bacteriophage ΦEF24C with a spontaneous point mutation.

Authors:  Jumpei Uchiyama; Iyo Takemura; Miho Satoh; Shin-ichiro Kato; Takako Ujihara; Kazue Akechi; Shigenobu Matsuzaki; Masanori Daibata
Journal:  PLoS One       Date:  2011-10-25       Impact factor: 3.240

Review 7.  An emptying quiver: antimicrobial drugs and resistance.

Authors:  J Todd Weber; Patrice Courvalin
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

8.  Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action.

Authors:  Jean Carlet; Vincent Jarlier; Stephan Harbarth; Andreas Voss; Herman Goossens; Didier Pittet
Journal:  Antimicrob Resist Infect Control       Date:  2012-02-14       Impact factor: 4.887

9.  Antibiotic resistance - why is the problem so difficult to solve?

Authors:  Sören Höjgård
Journal:  Infect Ecol Epidemiol       Date:  2012-08-20

10.  Antimicrobial drug resistance, regulation, and research.

Authors:  Joshua P Metlay; John H Powers; Michael N Dudley; Keryn Christiansen; Roger G Finch
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.